Lakewood-Amedex Nu-3 Phase 2a Trial Cleared
Analysis based on 8 articles · First reported Sep 18, 2026 · Last updated Sep 24, 2026
The news is a modest positive for Lakewood-Amedex as it de-risks near-term clinical progress on its lead asset, though the small-cap clinical-stage profile and absence of efficacy data limit broad market reaction. Sector impact is minimal, with attention confined to the antimicrobial and wound-care niche rather than the wider biotech or pharmaceutical complex.
Lakewood-Amedex Biotherapeutics Inc. announced that it has obtained central and all site Institutional Review Board (IRB) approvals and confirmed clinical trial site readiness to commence its Phase 2a clinical trial of its lead product candidate Nu-3 in patients with mildly infected diabetic foot ulcers (iDFU). Nu-3 is a proprietary topical gel from the company's Bisphosphocin class of fast-acting, broad-spectrum antimicrobials that destabilizes microbial cell membranes, offering a high barrier to antimicrobial resistance. The trial builds on positive preclinical safety data and early exploratory results showing Nu-3 was well-tolerated with trends of improved antimicrobial response and wound healing. Chief Medical Officer Thomas Balzer called the milestones a significant step forward in addressing drug-resistant wound infections, and noted the guidance of Study Chair David G. Armstrong. The company framed the effort as aligned with federal mandates from the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB). The announcement was distributed via multiple press release channels and the company was also highlighted as a new B2i Digital Featured Company. No trial start date, enrollment figures, or financial terms were disclosed.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard